Spark Therapeutics Inc (NASDAQ:ONCE) – Analysts at Wedbush lowered their Q1 2018 earnings estimates for Spark Therapeutics in a note issued to investors on Tuesday. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will earn ($1.88) per share for the quarter, down from their prior forecast of ($1.80). Wedbush has a “Underperform” rating and a $35.00 price target on the stock. Wedbush also issued estimates for Spark Therapeutics’ Q2 2018 earnings at ($1.88) EPS, Q3 2018 earnings at ($1.90) EPS, Q4 2018 earnings at ($1.92) EPS, FY2018 earnings at ($7.57) EPS, FY2019 earnings at ($6.59) EPS, FY2020 earnings at ($5.62) EPS, FY2021 earnings at ($4.60) EPS and FY2022 earnings at ($3.22) EPS.

A number of other equities analysts also recently issued reports on ONCE. SunTrust Banks set a $101.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Monday, October 16th. Credit Suisse Group assumed coverage on shares of Spark Therapeutics in a report on Wednesday. They issued an “outperform” rating and a $61.00 price objective on the stock. Raymond James Financial set a $66.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Royal Bank of Canada dropped their price objective on shares of Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Wednesday, November 8th. Finally, Cantor Fitzgerald set a $105.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $74.45.

Spark Therapeutics (NASDAQ:ONCE) opened at $51.48 on Thursday. The stock has a market cap of $1,899.12, a P/E ratio of -7.13 and a beta of 3.14. Spark Therapeutics has a 1-year low of $41.06 and a 1-year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). The business had revenue of $1.90 million during the quarter, compared to analysts’ expectations of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.07) EPS.

Several institutional investors have recently added to or reduced their stakes in ONCE. Ameritas Investment Partners Inc. raised its position in shares of Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Spark Therapeutics during the second quarter valued at approximately $143,000. BNP Paribas Arbitrage SA raised its position in shares of Spark Therapeutics by 530.1% during the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 2,449 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in shares of Spark Therapeutics during the third quarter valued at approximately $225,000. Finally, Prudential Financial Inc. bought a new stake in shares of Spark Therapeutics during the third quarter valued at approximately $239,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.

In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 20,000 shares of Spark Therapeutics stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $71.54, for a total transaction of $1,430,800.00. Following the transaction, the chief executive officer now owns 250,000 shares of the company’s stock, valued at $17,885,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Daniel Faga sold 6,000 shares of Spark Therapeutics stock in a transaction that occurred on Friday, October 20th. The shares were sold at an average price of $79.95, for a total transaction of $479,700.00. Following the transaction, the insider now directly owns 6,000 shares in the company, valued at approximately $479,700. The disclosure for this sale can be found here. Insiders have sold 62,309 shares of company stock worth $4,621,085 in the last ninety days. Insiders own 7.30% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://theolympiareport.com/2018/01/18/q1-2018-eps-estimates-for-spark-therapeutics-inc-reduced-by-wedbush-once.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.